Listen
IASOglio (fluoroethyl-L tyrosine (18F) or FET), radiopharmaceutical for diagnostic use for the detection of tumours
DIAGNOSTIC MEDICINAL PRODUCT - New medicinal product
Opinions on drugs -
Posted on
Nov 03 2016
Reason for request
Inclusion
- IASOglio has Marketing Authorisation in the diagnosis of gliomas by positron emission tomography (PET) imaging.
- It allows characterisation of glioma-like brain lesions, biopsy guidance in the case of glioma-like brain lesions, grading of gliomas, definition of the limits of viable tumour tissue prior to radiotherapy and detection of viable tumour masses in cases of a suspected persistent or recurrent glioma.
- No superiority has been shown relative to the comparators (brain MRI or PET with 18F‑fluorodopa).
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
